^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FCGR2B expression

    i
    Other names: FCGR2B, Fc Fragment Of IgG Receptor IIb, Low Affinity Immunoglobulin Gamma Fc Region Receptor II-B, Fc Fragment Of IgG Low Affinity IIb Receptor For (CD32), Fc Fragment Of IgG Low Affinity IIb Receptor (CD32), Fc Gamma Receptor IIb, IgG Fc Receptor II-B, Fc-Gamma RII-B, Fc-Gamma-RIIb, FcRII-B, CDw32, IGFR2, FCG2, CD32, Low Affinity Immunoglobulin Gamma Fc Region Receptor II-C, Fc Fragment Of IgG Low Affinity II Receptor For (CD32), IgG Fc Receptor II-C, Fc-Gamma RII-C, Fc Gamma RIIb, Fc-Gamma-RIIc, CD32 Antigen, FcRII-C, FCGR2C, CD32B, FCGR2
    Entrez ID:
    2213
    Related biomarkers:
    Mutation
    over1year
    The cGAS/STING signaling pathway is involved in sevoflurane induced neuronal necroptosis via regulating microglia M1 polarization. (PubMed, Cell Signal)
    These results suggest that sevoflurane can regulate microglial M1 polarization by activating the cGAS/STING signaling pathway and increasing immune factor release, thus accelerating the neuronal necroptosis induced by calcium overload.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • STING (stimulator of interferon response cGAMP interactor 1) • FCGR2A (Fc fragment of IgG receptor IIa) • CGAS (Cyclic GMP-AMP Synthase) • FCGR2B (Fc Fragment Of IgG Receptor IIb) • RIPK1 (Receptor Interacting Serine/Threonine Kinase 1) • MLKL (Mixed Lineage Kinase Domain Like Pseudokinase)
    |
    FCGR2B expression
    2years
    Unveiling Novel Therapeutic Targets for CAR Therapy in Multiple Myeloma through Single-Cell RNA Sequencing (ASH 2023)
    Additionally, this approach led us to identify a series of potential new targets for MM patients, depicting a new scenario where each patient could be “screened” to identify the best molecule to be targeted. While further investigation is necessary to assess off-target toxicity and confirm clinical relevance, our analyses significantly streamline the search for tumor markers with a method potentially applicable to different malignancies, bringing us closer to identifying the best candidates for effective CAR therapy.
    IO biomarker
    |
    FGFR3 (Fibroblast growth factor receptor 3) • CD38 (CD38 Molecule) • TNFRSF17 (TNF Receptor Superfamily Member 17) • SDC1 (Syndecan 1) • CCND2 (Cyclin D2) • IR (Insulin receptor) • FCGR2B (Fc Fragment Of IgG Receptor IIb) • MAF (MAF BZIP Transcription Factor) • CD59 (CD59 Molecule) • FCRLB (Fc Receptor Like B) • SLAMF7 (SLAM Family Member 7) • TNFRSF13B (TNF Receptor Superfamily Member 13B)
    |
    FCGR2B expression
    2years
    FCGR2B as a prognostic and immune microenvironmental marker for gliomas based on transcriptomic analysis. (PubMed, Medicine (Baltimore))
    FCGR2B may play an important role in the occurrence, development and invasion of tumor by influencing the tumor microenvironment of immunosuppression. FCGR2B may be an important target for the treatment of glioma.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • PD-L2 (Programmed Cell Death 1 Ligand 2) • CD48 (CD48 Molecule) • FCGR2B (Fc Fragment Of IgG Receptor IIb) • LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1) • TNFSF14 (TNF Superfamily Member 14)
    |
    FCGR2B expression
    almost3years
    Fc gamma receptor IIb in tumor-associated macrophages and dendritic cells drives poor prognosis of recurrent glioblastoma through immune-associated signaling pathways. (PubMed, Front Genet)
    In clinical specimens, FcγRIIb-positive cell populations were higher in recurrent GBM than in primary GBM. This study provides novel insights into the role of FcγRIIb in recurrent GBM and a promising strategy for treatment as an immune therapeutic target.
    Journal
    |
    FCGR2B (Fc Fragment Of IgG Receptor IIb)
    |
    FCGR2B expression
    3years
    Effect of M1 microglia-derived exosomal microRNA-20a-5p on neuronal injury after oxygen-glucose deprivation and restoration injury (PubMed, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue)
    M1 microglia-derived exosomes aggravate the injury of neurons after oxygen and glucose deprivation and reoxygenation, which may be related to miR-20a-5p carried by M1-exo.
    Journal
    |
    IFNG (Interferon, gamma) • CD9 (CD9 Molecule) • FCGR2A (Fc fragment of IgG receptor IIa) • FCGR2B (Fc Fragment Of IgG Receptor IIb) • MIR20A (MicroRNA 20a)
    |
    FCGR2B expression
    3years
    Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy. (PubMed, J Transl Med)
    These results indicated the importance of IL-15 in enhancing T cells persistence and IL-15Ra in reducing the adverse effects of IL-15, with superior tumor retardation during CAR-T therapy. This study paves the way for the rapid exploitation of IL-15 in adoptive cell therapy in the future.
    Journal • IO biomarker
    |
    CD19 (CD19 Molecule) • IFNG (Interferon, gamma) • IL2 (Interleukin 2) • FCGR2A (Fc fragment of IgG receptor IIa) • FCGR2B (Fc Fragment Of IgG Receptor IIb) • IL15 (Interleukin 15)
    |
    FCGR2B expression
    over3years
    Trial in progress: A phase 1-2, first-in-human, open label, dose escalation and expansion study of AU-007, a monoclonal antibody that binds to IL-2 and inhibits IL-2Rα binding, in patients with advanced solid tumors. (ASCO 2022)
    Thus, AU-007 redirects endogenously produced or exogenous IL-2 (aldesleukin) towards activation of immune stimulating T effector and NK cells, while diminishing Treg activation and expansion. Patients with advanced melanoma, RCC and other tumors including, but not limited to, Merkel Cell Carcinoma, NSCLC, and urothelial cancer are eligible. Enrolment to the study commences in Australia, with US sites planned to open later in 2022.
    Clinical • P1/2 data
    |
    IL2RA (Interleukin 2 receptor, alpha) • IL2 (Interleukin 2) • FCGR2A (Fc fragment of IgG receptor IIa) • FCGR2B (Fc Fragment Of IgG Receptor IIb)
    |
    FCGR2B expression
    |
    Proleukin (aldesleukin) • imneskibart (AU-007)
    4years
    Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia. (PubMed, J Hematol Oncol)
    CD32b is not significantly expressed by non-B hematopoietic cells. Our study thus identifies CD32b as a potential target of CAR-T cell therapy for CLL, although further modification of the CAR construct with a safety mechanism may be required to minimize off-target toxicity.
    Journal • IO biomarker
    |
    CD19 (CD19 Molecule) • FCGR2A (Fc fragment of IgG receptor IIa) • FCGR2B (Fc Fragment Of IgG Receptor IIb)
    |
    FCGR2B expression
    4years
    Low Dose Cyclophosphamide in Combination with Elotuzumab - a Novel Immunotherapeutic Strategy for Multiple Myeloma (ASH 2021)
    Combining CTX with monoclonal antibody (mAb) therapy has proven beneficial in potentiating relapsed and/or refractory multiple myeloma (RRMM) therapies, with daratumumab-directed MM cell death enhanced in the presence of CTX 2,3...ELO has been approved for use alongside dexamethasone and lenalidomide 4 or pomalidomide (POM) 5...Given the increased expression of PD-1 and CD47, we investigated if the inclusion of nivolumab and anti-CD47 mAbs potentiated ADCC...2020 10:91 Hose et al ., Journal of Cancer Research and Clinical Oncology. 2021; 147:205–212
    Combination therapy • PD(L)-1 Biomarker • IO biomarker
    |
    CD47 (CD47 Molecule) • FCGR2A (Fc fragment of IgG receptor IIa) • CD2 (CD2 Molecule) • FCGR2B (Fc Fragment Of IgG Receptor IIb) • NKG2D (killer cell lectin like receptor K1)
    |
    PD-1 expression • FCGR2B expression
    |
    Opdivo (nivolumab) • lenalidomide • cyclophosphamide • Darzalex (daratumumab) • dexamethasone • pomalidomide • Empliciti (elotuzumab)